Last reviewed · How we verify
Placebo/Janagliflozin
Janagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney, promoting urinary glucose excretion and lowering blood glucose levels.
Janagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney, promoting urinary glucose excretion and lowering blood glucose levels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Placebo/Janagliflozin |
|---|---|
| Sponsor | Sihuan Pharmaceutical Holdings Group Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT2 (sodium-glucose cotransporter 2) inhibitors work by preventing the reabsorption of filtered glucose in the proximal tubule of the nephron. By blocking this transporter, the drug increases urinary glucose excretion (glycosuria), thereby reducing blood glucose independently of insulin secretion. This mechanism also provides cardiovascular and renal protective benefits beyond glucose lowering.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Osmotic diuresis-related symptoms
Key clinical trials
- Janagliflozin Treat T2DM Monotherapy (PHASE3)
- Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo/Janagliflozin CI brief — competitive landscape report
- Placebo/Janagliflozin updates RSS · CI watch RSS
- Sihuan Pharmaceutical Holdings Group Ltd. portfolio CI